Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$29.88 USD
+0.17 (0.57%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $29.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Harmony Biosciences Holdings, Inc. (HRMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$44.75 | $59.00 | $28.00 | 50.62% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Harmony Biosciences Holdings, Inc. comes to $44.75. The forecasts range from a low of $28.00 to a high of $59.00. The average price target represents an increase of 50.62% from the last closing price of $29.71.
Analyst Price Targets (8 )
Broker Rating
Harmony Biosciences Holdings, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on nine recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 22.22%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
4/9/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
3/28/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
2/16/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
9/7/2023 | Berenberg Bank | Caroline H Palomeque | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $44.75 |
LT Growth Rate | 22.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.04 |